A personalized evaluation can help determine which option aligns best with your needs, ensuring both safety and effectiveness in your weight management journey
The STEP clinical trial series demonstrated that weekly semaglutide 2.4 mg achieved 16.8% average weight loss in patients with obesity but without diabetes over 68 weeks, significantly better than placebo
Clinical evidence from the STEP trials demonstrated that participants lost an average of 10% to 22% of their baseline body weight over 68 weeks, depending on the dose
Of course, adverse effects can appear less frequently and are severe, therefore it is recommended to be discussed with your healthcare provider before the start of the peptide treatment
Its not just about what the scale says but about how your body works, feels, and recovers each week
The same logic behind converting tirzepatide units to milligrams applies here, just with different concentration values